Yanuki
Finance / Stocks
Pfizer (PFE) presents a compelling case for value investors, trading at a low valuation with a high dividend yield. However, concerns about upcoming patent expirations and revenue decline leave investors wondering: Is Pfizer an undervalued...
Finance / Pharma
Pfizer (PFE) is strategically re-entering the competitive GLP-1 market, targeting the rapidly expanding obesity drug sector. With the acquisition of Metsera for $4.9 billion, Pfizer aims to secure a significant position in this lucrative ma...
Finance / Pharma
Pfizer (PFE) is strategically expanding its pipeline in the GLP-1 obesity market through the acquisition of Metsera. This move aims to strengthen Pfizer's position in the rapidly growing weight management sector, projected to reach $150 bil...
Finance / Company News
Pfizer (PFE) has revised its full-year adjusted profit guidance upward for 2025, driven by successful cost-cutting initiatives and robust business performance. This adjustment comes as the pharmaceutical giant navigates ongoing challenges r...
